PharmaBlock Sciences Nanjing Inc Class A Asset Resilience Ratio
PharmaBlock Sciences Nanjing Inc Class A asset resilience ratio. PharmaBlock Sciences Nanjing Inc Class A (300725) has an Asset Resilience Ratio of 11.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300725 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PharmaBlock Sciences Nanjing Inc Class A (2014–2025)
Asset resilience ratio of PharmaBlock Sciences Nanjing Inc Class A from 2014 to 2025. This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Asset Resilience Ratio has changed over time. Read PharmaBlock Sciences Nanjing Inc Class A debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PharmaBlock Sciences Nanjing Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PharmaBlock Sciences Nanjing Inc Class A (300725) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥592.96 Million | 11.01% |
| Total Liquid Assets | CN¥592.96 Million | 11.01% |
Asset Resilience Insights
- Moderate Liquidity: PharmaBlock Sciences Nanjing Inc Class A has 11.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
PharmaBlock Sciences Nanjing Inc Class A Industry Peers by Asset Resilience Ratio
Compare PharmaBlock Sciences Nanjing Inc Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
PharmaBlock Sciences Nanjing Inc Class A Asset Resilience Ratio by Year (2014–2025)
PharmaBlock Sciences Nanjing Inc Class A asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for PharmaBlock Sciences Nanjing Inc Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.02% | CN¥735.57 Million ≈ $107.64 Million |
CN¥7.34 Billion ≈ $1.07 Billion |
+0.59pp |
| 2024-12-31 | 9.43% | CN¥465.61 Million ≈ $68.13 Million |
CN¥4.94 Billion ≈ $722.19 Million |
-11.91pp |
| 2023-12-31 | 21.35% | CN¥1.09 Billion ≈ $159.44 Million |
CN¥5.10 Billion ≈ $746.88 Million |
+17.99pp |
| 2022-12-31 | 3.36% | CN¥163.30 Million ≈ $23.90 Million |
CN¥4.86 Billion ≈ $711.49 Million |
-5.32pp |
| 2021-12-31 | 8.68% | CN¥304.43 Million ≈ $44.55 Million |
CN¥3.51 Billion ≈ $513.17 Million |
+4.24pp |
| 2020-12-31 | 4.44% | CN¥107.62 Million ≈ $15.75 Million |
CN¥2.43 Billion ≈ $354.90 Million |
+2.35pp |
| 2019-12-31 | 2.09% | CN¥21.52 Million ≈ $3.15 Million |
CN¥1.03 Billion ≈ $150.60 Million |
+0.12pp |
| 2014-12-31 | 1.97% | CN¥2.00 Million ≈ $292.66K |
CN¥101.56 Million ≈ $14.86 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more